Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
Interested participants and investors may access the conference call at5 p.m. ET by dialing 877-419-6591 (U.S./Canada) or 719-325-4858(international). A telephonic replay of the call will be available for sevendays beginning at 8 p.m. ET. Access numbers for this replay are 888-203-1112(U.S./Canada) and 719-457-0820 (international); participant code 4499321.
An audio webcast can also be accessed via the investor section of theAmicus Therapeutics Web site at http://www.amicustherapeutics.com underInvestors: Events and Presentations. Web participants are encouraged to go tothe Web site 15 minutes prior to the start of the call to register, downloadand install any necessary software. After the live webcast, a webcast replaywill remain available in the Investors section of the Amicus Therapeutics Website for 30 days.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oraltherapeutics known as pharmacological chaperones for the treatment of a rangeof human genetic diseases. Pharmacological chaperone technology involves theuse of small molecules that selectively bind to and stabilize proteins incells, leading to improved protein folding and trafficking, and increasedactivity. Amicus is initially targeting lysosomal storage disorders, which aresevere, chronic genetic diseases with unmet medical needs. Amicus hascompleted Phase 2 clinical trials of Amigal for the treatment of Fabry diseaseand is conducting Phase 2 clinical trials of Plicera for the treatment ofGaucher disease and AT2220 for the treatment of Pompe disease.
Amicus' press releases are available at http://www.amicustherapeutics.com
SOURCE Amicus Therapeutics
You May Also Like